hackint0sh/New-Dataset huggingface dataset:
Enrolled participants will complete an online survey with questions about having a son with Rett Syndrome. The Diagnostic Experience of Male Rett Syndrome study is available to parents or caregivers to boys (alive or passed) with Rett Syndrome. Compensation is not provided. conditions: Rett Syndrome conditions: RTT studyType: OBSERVATIONAL observationalModel: FAMILY_BASED timePerspective: RETROSPECTIVE count: 80 type: ESTIMATED name: Male Rett measure: Diagnostic experiences measure: Attainment of developmental milestones and any regressions measure: QI-disability measure: Parent priorities for care and counseling measure: Parenting experience measure: Information regarding child's death, if applicable measure: Family demographics measure: Systems of supports measure: Healthcare preferences sex: MALE minimumAge: 0 Years maximumAge: 100 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University of Colorado Anschutz Medical Campus status: RECRUITING city: Aurora state: Colorado zip: 80045 country: United States name: Natalia Klamut role: CONTACT phone: 720-277-9095 email: malerettstudy@cuanschutz.edu name: Timothy Benke, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Talia Thompson, PhD role: SUB_INVESTIGATOR lat: 39.72943 lon: -104.83192 hasResults: False
nctId: NCT06346093 id: CHEC2024-089 briefTitle: Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2026-12-31 date: 2026-12-31 date: 2024-04-03 date: 2024-04-03 name: Xiangyu Kong class: OTHER briefSummary: This study is a randomized, double-blind and placebo-controlled study. The purpose of this study is to evaluate the efficacy and safety of FMT capsules combined with chemotherapy and anti-PD-L1 therapy in the advanced gastric cancer. conditions: Advanced Gastric Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 66 type: ESTIMATED name: Fecal Microbiota Transplantation Capsules name: Placebo measure: Objective response rate (ORR) measure: Rate of Disease Control measure: Progression-free Survival (PFS) measure: Overall Survival (OS) measure: Incidence of Adverse Events Related to Treatment measure: Change in the intestinal microbiome community measure: Quality of life based on the questionnaire measure: Quality of life based on the questionnaire measure: Change in the immunity measure: Marker of nutritional status measure: Marker of nutritional status measure: Marker of nutritional status measure: Body Weight measure: Appetite measure: Marker of nutritional status measure: Marker of nutritional status sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Changhai Hospital city: Shanghai state: Shanghai zip: 200433 country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06346080 id: s68670 briefTitle: Molecular Analysis for Gastro-Esophageal Cancer: Multicenter Discrete Choice Experiment acronym: MAGECmultiDiCE overallStatus: NOT_YET_RECRUITING date: 2024-08-01 date: 2026-08-01 date: 2026-08-01 date: 2024-04-03 date: 2024-04-03 name: KU Leuven class: OTHER briefSummary: The goal of this survey is to investigate the participants' preference for a specific screening/diagnostic tool to detect and assess gastro-esophageal cancer.
Participants will be asked to complete a survey of 20-25min, including a brief intake regarding their socio-economic status. This approach will allow us to correct for confounding factors. conditions: Esophageal Cancer conditions: Gastric Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: A survey will be conducted in a single group of participants from different geographical regions and backgrounds primaryPurpose: OTHER masking: NONE count: 2200 type: ESTIMATED name: Survey measure: The rate of contribution of diagnostic features to the preference of participants measure: The percentage differences in preference of participants between geographical regions measure: Assess the rate patient-level demographics influence the importance of a test feature, expressed as an odds ratio measure: Assess the rate of trade-off demonstrated as odds ratio between cancer-related mortality reduction and costs sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06346067 id: ERAS-254-02 briefTitle: A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2028-04 date: 2028-12 date: 2024-04-03 date: 2024-04-29 name: Erasca, Inc. class: INDUSTRY briefSummary: Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2.
Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy). conditions: Advanced or Metastatic NRAS-mutant Melanoma studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 470 type: ESTIMATED name: Naporafenib name: Dacarbazine name: Temozolomide name: Trametinib measure: Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2 measure: Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2 measure: Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2 measure: Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2 measure: Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2 measure: Stage 2: To compare PFS and OS for patients who are randomized to receive the combination of naporafenib + trametinib to that of patients who receive physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy) measure: Adverse Events measure: Duration of Response (DOR) measure: Time to Response (TTR) measure: Disease Control Rate (DCR) measure: Overall Response Rate (ORR) measure: Plasma concentration (Cmax):Stage 1 only measure: Area under the curve (AUC):Stage 1 only measure: Quality of Life: To assess disease and treatment-related QOL in patients with NRASm melanoma. measure: Duration of Response (DOR) for CNS disease in participants measure: Overall Response Rate (ORR) for CNS disease in participants measure: Disease Control Rate (DCR) for CNS disease in participants sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: SCRI Oncology Partners (formerly Tennessee Oncology) city: Nashville state: Tennessee zip: 37203 country: United States lat: 36.16589 lon: -86.78444 hasResults: False
nctId: NCT06346054 id: s68669 briefTitle: Molecular Assessment for Gastro-Esophageal Cancer acronym: MAGEC overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2029-07-01 date: 2029-07-01 date: 2024-04-03 date: 2024-04-03 name: KU Leuven class: OTHER briefSummary: The goal of this minimally invasive interventional study is to learn if oncometabolic biomarkers, detected in the exhaled breath and blood can identify early-stage gastro-oesophageal cancer in patient at risk for gastro-oesophageal cancer.
Participants will provide a breath and blood sample during their routine standard of care visits. conditions: Esophageal Cancer conditions: Gastric Cancer conditions: Barrett Esophagus studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants with gastro-esophageal cancer, participants with Barrett's esophagus and Healthy controls will be monitored in parallel to identify oncometabolic biomarkers related to cancer primaryPurpose: DIAGNOSTIC masking: NONE count: 1000 type: ESTIMATED name: Breath analysis name: Blood analysis measure: Identification of the concentrations of oncometabolites measure: Assessment of incidence of early-stage cancer measure: Assessment of incidence of therapy response measure: Assessment of percentage change of therapy response measure: Assessment of incidence of recurrence sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06346041 id: HJG-IDOV-SAFE-LYSW briefTitle: Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-12-31 date: 2026-04-01 date: 2024-04-03 date: 2024-04-03 name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences class: OTHER briefSummary: This is an open-label, dose escalation, phase I study to evaluate safety tolerability, MTD or MFD, pharmacokinetic profile, immunogenicity, and pharmacodynamic profile of IDOV-SAFETM in patients with advanced solid tumors. conditions: Neoplasms studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 19 type: ESTIMATED name: Oncolytic Virus injection(IDOV-SAFETM) measure: Dose Limiting Toxicities (DLT) measure: Incidence of adverse events and severe adverse events measure: MTD/MFD measure: The Pharmacokinetics characteristics of IDOV-SAFETM((biological distribution and viral expulsion)) measure: Immunogenicity of IDOV-SAFETM measure: ORR measure: DCR measure: DOR measure: PFS measure: OS sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06346028 id: 2023/086 briefTitle: Implementation of Transcranial Magnetic Stimulation for Smoking Cessation overallStatus: RECRUITING date: 2024-03-30 date: 2025-06-30 date: 2025-06-30 date: 2024-04-03 date: 2024-04-03 name: Centre for Addiction and Mental Health class: OTHER briefSummary: Repetitive transcranial magnetic stimulation (rTMS) is an alternative non-invasive treatment to help people quit smoking. rTMS uses a magnetic field to stimulate regions of the brain that are involved in addiction. The two brain regions that are stimulated are the insula and the dorsolateral prefrontal cortex, which are involved in drug craving and decision-making, respectively.
• Learning about the feasibility of rTMS as a treatment option for patients in the NDC will help us improve the treatment when offering it in other clinics, which may help improve smoking quit rates and people's overall health. conditions: Smoking studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Brainsway H4 deep rTMS coil and Brainsway stimulator system measure: The primary objective of the study is to evaluate the feasibility of implementing rTMS in the Nicotine Dependence Clinic (NDC) at CAMH, in Toronto. This is determine by reach, the extent to which patients are engaging in the rTMS treatment. measure: Identify rates of adoption of rTMS in Nicotine Dependence Clinic measure: Identify contextual determinants of rTMS adoption and reach NDC through a qualitative approach. measure: Evaluate the effectiveness of rTMS on smoking cessation rates in real world patients with common comorbidities seeking treatment at NDC. measure: Explore patient-HCP communication about shared treatment decision-making for rTMS. sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Center for Addiction and Mental Health (CAMH) status: RECRUITING city: Toronto state: Ontario country: Canada name: Alexandra S, BScH role: CONTACT phone: 416-535-8501 phoneExt: 31551 email: rtms.smoking@camh.ca lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06346015 id: HX-A-2023050 briefTitle: Gamma Entrainment Stimulation for Cognitive Dysfunction After aSAH acronym: GES-aSAH overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-03-31 date: 2025-03-31 date: 2024-04-03 date: 2024-04-03 name: Beijing Tiantan Hospital class: OTHER name: Shanghai Joyingmed Sensory Stimulation Lab briefSummary: The goal of this clinical trial is to Explore and verify whether 40Hz audio and binaural beat 40Hz audio can improve the postoperative cognitive dysfunction seen in patients with aneurysmal subarachnoid hemorrhage. This study is a single-center, prospective, randomized, controlled clinical trial. Patients with aneurysmal subarachnoid hemorrhage were selected and randomized into intervention group (audio adjuvant group) and control group (conventional treatment group). Patients in the intervention group will receive audio therapy after surgery, and patients in the control group will receive usual care. EEG, fMRI and mRS scores were evaluated after 3 months of follow-up. conditions: Subarachnoid Hemorrhage, Aneurysmal conditions: Cognitive Dysfunction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The relevant neuroimaging evaluation process is blinded to the evaluator to ensure the objectivity of the evaluation results. whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Gamma Entrainment Stimulation measure: Montreal Cognitive Assessment (MoCA) scores < 22 measure: mini-mental state examiniation (MMSE) < 27 measure: modified Rankin Scales (mRS) > 2 measure: electroencephalogram (EEG) indicators measure: functional Magnetic Resonance Imaging (fMRI) indicators measure: Safety indicator sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06346002 id: 2026_e_2017 briefTitle: Impact of a Mindfulness-based Intervention on Well-being and Mental Health of Elementary School Children overallStatus: COMPLETED date: 2017-03-01 date: 2020-03-31 date: 2020-03-31 date: 2024-04-03 date: 2024-04-03 name: Bishop's University class: OTHER briefSummary: Background: Prevention programs for children such as mindfulness-based interventions (MBIs) are often implemented in schools to prevent psychological disorders from emerging and contribute to children' mental health.
Method: 13 elementary school classrooms were randomly allocated to the experimental condition (7 classrooms, n = 127 students) or the waitlist control condition (6 classrooms, n = 104 students). Participants in the experimental condition received a 10-week MBI. conditions: Mindfulness-based Intervention conditions: Elementary School Children conditions: Mental Health Wellness 1 studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized cluster trial with a wait-list control primaryPurpose: PREVENTION masking: NONE count: 231 type: ACTUAL name: Mindfulness-based intervention measure: Symptoms of Mental Health Disorders measure: Basic Psychological Needs Satisfaction measure: Process Measure sex: ALL minimumAge: 8 Years maximumAge: 12 Years stdAges: CHILD facility: École primaire Préville city: Saint-Lambert state: Quebec zip: J4S 1M8 country: Canada lat: 45.50008 lon: -73.51028 hasResults: False
nctId: NCT06345989 id: 187157 briefTitle: Time and Cost-implications of Intraoral Scans vs Alginate Impressions: A Randomised Controlled Trial overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-06 date: 2025-12 date: 2024-04-03 date: 2024-04-03 name: University of Sheffield class: OTHER name: Nottingham University Hospitals NHS Trust briefSummary: This research project investigates the time and cost implications of two common techniques in orthodontics: alginate impressions and intraoral scans. Alginate impressions (putty moulds) are a traditional technique that has been used in orthodontic practice for many years. Intraoral scans are a more modern method and are becoming more commonly used in orthodontic practice. Both alginate impressions and intraoral scans are a means of recording a copy of a patient's teeth which aids in record keeping and treatment planning.
The outcomes of this study will provide important insights into the practicality and economic viability of intraoral scanning versus alginate impressions in orthodontic settings, thereby informing clinical practices within the United Kingdom. This research contributes to strengthening the evidence base surrounding orthodontic techniques and their implications for patient-centred care. conditions: Chairside Time and Costs Associated With Intraoral Scanning Versus Alginate Impressions studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Prospective single-centre parallel arm randomised controlled trial, with an allocation ratio of 1:1 to investigate the difference in chairside time and cost of alginate impressions vs intraoral scans. primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE maskingDescription: Due to the nature of the study, blinding to intervention will not be possible for the participants or clinicians during data acquisition. All data analysis will be carried out blinded using a coded data set. whoMasked: OUTCOMES_ASSESSOR count: 68 type: ESTIMATED name: Alginate impression name: Intraoral scan measure: Chairside time taken for alginate impressions vs intraoral scans. measure: Cost implications of alginate impressions vs intraoral scans. sex: ALL minimumAge: 9 Years maximumAge: 50 Years stdAges: CHILD stdAges: ADULT facility: Queens Medical Centre, Nottingham University Hospitals NHS Trust city: Nottingham state: Nottinghamshire zip: NG7 2UH country: United Kingdom name: Hannah Hook, BDS role: CONTACT phone: 07853993215 email: hannah.hook@nuh.nhs.uk name: Andrew Flett, BDS role: CONTACT email: andrew.flett@nuh.nhs.uk lat: 52.9536 lon: -1.15047 hasResults: False
nctId: NCT06345976 id: RLX_2023_10 briefTitle: Functional Impairment in Albinism acronym: PLAIB overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2025-05 date: 2024-04-03 date: 2024-04-03 name: Fondation Ophtalmologique Adolphe de Rothschild class: NETWORK briefSummary: Albinism is a genetic and hereditary anomaly that affects pigmentation. This pathology is characterized by a deficit in melanin production. In humans, the clinical diagnosis of albinism is based on a number of factors, including :
As treatment options begin to emerge for certain albinism-induced anomalies (including, for example, the depigmentation that causes photophobia), it is desirable to understand what these patients' complaints are, and to gather their views on the emergence of treatments targeting just one of their complaints, namely glare. conditions: Albinism, Ocular studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: questionnaire measure: To determine whether patients with albinism would be interested in a treatment that could improve their glare without improving their visual acuity. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06345963 id: HSC-MS-23-1044 briefTitle: Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1) overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2029-05-01 date: 2030-05-01 date: 2024-04-03 date: 2024-04-05 name: The University of Texas Health Science Center, Houston class: OTHER briefSummary: Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil for improving white matter integrity. conditions: Schizophrenia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: active H-coil delivered rTMS measure: brain microstructural integrity from magnetic resonance imaging (MRI) measure: Resting-state functional connectivity (rsFC) from functional MRI measure: Electrophysiological responses measured by mismatch negativity and steady-state auditory evoked potentials from electroencephalography recording (EEG) measure: Cognitive insight, depression, perception, and delusion measured from questionnaires measure: Cognitive functions measured by the MATRICS consensus cognitive battery (MCCB) sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: The University of Texas Health Science Center, Houston city: Houston state: Texas zip: 77054 country: United States name: Xiaoming Du, PhD role: CONTACT phone: 410-402-6036 email: Xiaoming.Du@uth.tmc.edu name: Victoria Acosta role: CONTACT phone: 713-486-2740 email: Victoria.Acosta@uth.tmc.edu lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06345950 id: 2022-04-003 briefTitle: Pharmacokinetics and Safety of a New Micellar Glutathione Formulation overallStatus: COMPLETED date: 2022-06-21 date: 2022-12-31 date: 2023-06-30 date: 2024-04-03 date: 2024-04-03 name: Factors Group of Nutritional Companies Inc. class: INDUSTRY name: Isura briefSummary: This study seeks to determine the short-term effects of daily oral supplementation with a new micellar Glutathione formulation (LipoMicel) on the oral absorption and safety of glutathione in healthy volunteers.
The primary objective of this study is to evaluate and compare the pharmacokinetics of a novel micellar Glutathione (GSH) formulation with that of a standard formulation as well as a liposomal GSH formulation. The secondary objective is to evaluate the safety of a new micellar GSH formulation with higher bioavailability in human participants over a 30-day study period. conditions: Bioavailability conditions: Safety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Participants are randomly assigned to interventions in a crossover design to assess the pharmacokinetics over 24 hours; subsequently, the safety of one intervention with higher bioavailability is evaluated in an additional single-arm, 30-day trial. primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 16 type: ACTUAL name: Liposomal Glutathione name: Standard Glutathione name: New Micellar Glutathione (Lipomicel) measure: AUC: the area under the concentration-time curve measure: Cmax: maximum plasma concentration measure: Tmax: the time point of maximum plasma concentration measure: Alanine aminotransferase (ALT) measure: Aspartate aminotransferase (AST) measure: Alkaline phosphatase (ALP) measure: Bilirubin measure: Serum creatinine measure: Blood urea nitrogen (BUN) measure: Glomerular filtration rate (GFR) measure: C-reactive protein (CRP) measure: White blood cell count (WBC) measure: Hemoglobin (Hb) measure: Hematocrit (Hct) measure: Platelet count measure: Fasting blood glucose measure: Total cholesterol measure: Low-density lipoprotein (LDL) cholesterol measure: High-density lipoprotein (HDL) cholesterol measure: Triglycerides sex: ALL minimumAge: 21 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ISURA city: Burnaby state: British Columbia zip: V2N 4S9 country: Canada lat: 49.26636 lon: -122.95263 hasResults: False
nctId: NCT06345937 id: REB #44724 briefTitle: Multiple Risk Factor Intervention Trial (Ms. FIT) acronym: MsFIT overallStatus: RECRUITING date: 2024-04-01 date: 2027-08-01 date: 2028-08-01 date: 2024-04-03 date: 2024-04-04 name: University of Toronto class: OTHER name: Canadian Institutes of Health Research (CIHR) briefSummary: This study aims to produce new evidence, specific to women, on the efficacy and mechanisms of exercise and diet for cardiometabolic risk reduction in pre and postmenopausal women. Using a 3-arm randomized controlled trial (RCT) with equal recruitment and stratification by menopausal status to 6 months of: 1) exercise following Health Canada guidelines; 2) the same exercise plus counselling to follow Canada's Dietary Guidelines to improve diet quality; or 3) stretching group, this study will answer the following questions: